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ABSTRACT 24 
 25 
Background: The only disease modifying treatment of allergies is allergen-specific 26 
immunotherapy, which today is administered either subcutaneously or sublingually. In a pilot 27 
study we have recently shown that epicutaneous immunotherapy using a skin patch may be a 28 
promising treatment alternative. 29 
Objective: To find the optimal treatment dose and to demonstrate sustained clinical efficacy 30 
and safety of epicutaneous immunotherapy. 31 
Methods: This monocentric, placebo-controlled, double-blind trial included 132 patients 32 
with grass-pollen induced rhinoconjunctivitis. In February 2008, patients were randomly 33 
allocated to one of four treatment groups (placebo, 10HEP, 50HEP, 100HEP, n=33 each). 34 
Before and during the pollen season 2008, patients received 6 patches in total. Treatment 35 
efficacy was assessed at the end of the pollen season 2008 (n= 110) and after a subsequent 36 
treatment-free follow-up year 2009 (n=93). 37 
Results: A clear dose-dependency of patient self-reported hay-fever symptom alleviation was 38 
observed after the follow-up year, reaching statistical significance for the highest treatment-39 
dose group (100HEP) as compared to the placebo group (P<0.05). Seasonal hay-fever 40 
symptom scores were reduced by more than 30% in 2008 and by 24% in 2009 in the 100HEP 41 
group as compared to the placebo group. Higher allergen doses were associated with more 42 
drug-related adverse events, predominantly presenting as local reactions, such as pruritus, 43 
erythema, wheal and eczema. Eleven systemic allergic reactions (grade 0 to 2) needed 44 
treatment and led to study exclusion (adverse event induced drop-out rate: 8.3%). No drug-45 
related serious adverse events were reported.  46 
Conclusion: Epicutaneous immunotherapy is safe and efficacious in a dose-dependent 47 
manner after 6 patches only.  48 
49 
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Clinical implications 50 
Epicutaneous allergen-specific immunotherapy is a convenient, safe and efficacious 51 
treatment for IgE-mediated allergies leading to symptom alleviation after a single-treatment 52 
season. 53 
 54 
Capsule summary 55 
Due to the poor acceptance of long-term allergen-specific immunotherapy, there is a need to 56 
improve treatment convenience by offering a treatment option that is both needle-free and 57 
also confers symptom amelioration after short treatment duration. We propose that 58 
epicutaneous-allergen-specific immunotherapy could be such an alternative. 59 
 60 
Key words 61 
Epicutaneous allergen-specific immunotherapy, epicutaneous immunotherapy, Patch 62 
immunization 63 
 64 
65 
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Abbreviations 66 
 67 
AE  Adverse event 68 
AUC  Area under the curve 69 
BU  Biological unit 70 
CI  Confidence interval 71 
CPT  Conjunctival provocation test 72 
EPIT  Epicutaneous allergen-specific immunotherapy 73 
HEP  Histamine equivalent prick unit  74 
PRO  Patient-reported outcome 75 
SCIT  Subcutaneous allergen-specific immunotherapy 76 
SD  Standard deviation 77 
SIT  Allergen-specific immunotherapy 78 
SLIT  Sublingual allergen-specific immunotherapy 79 
SPT  Skin prick test 80 
VAS  Visual analogue scale 81 
82 
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INTRODUCTION 83 
 84 
Today, IgE-mediated allergies such as allergic rhinoconjunctivitis and asthma have reached a 85 
worldwide prevalence of 25%,1-4 and are therefore called ‘the new epidemics of the 21st 86 
century’.5 Although, not life-threatening, allergic rhinoconjunctivitis significantly reduces 87 
quality of life leading to physical discomfort, emotional stress and impaired social activity.6-88 
10 Furthermore, allergic rhinoconjunctivits is associated with high socioeconomic costs, not 89 
only due to work absenteeism and decreased productivity but also since it represents a risk 90 
factor for disease progression to allergic asthma requiring long-term pharmacotherapy.7 91 
Despite insufficient symptom control with pharmacotherapy,7, 11 only 5% of the patients 92 
suffering from allergic rhinoconjunctivitis decide to undergo allergen-specific 93 
immunotherapy (SIT),12-13 which is the only disease-modifying and long-lasting treatment 94 
option.14-15 Yet, the requirement for numerous doctor visits and the risk of treatment 95 
associated systemic allergic side effects limit the broad application of subcutaneous allergen 96 
specific immunotherapy (SCIT),14, 16 which has been introduced a century ago17 and still 97 
represents the ‘goldstandard’ route for SIT.4, 18 Aiming to increase acceptance of SIT, 98 
tremendous effort has been put into the development of more patient-convenient and self-99 
administrable treatment routes.19-20 With the consented approval of sublingual allergen-100 
specific immunotherapy (SLIT) as a valid needle-free treatment alternative to SCIT in 101 
1998,21 a new area of SIT has been initiated. Thanks to the excellent safety profile with rare 102 
systemic allergic side effects12, 22 SLIT can be self-administered and therefore represents an 103 
increasing percentiage of SIT treatments in Europe.18 However, up to 75% of patients report 104 
oral and gastrointestinal side effects12  and treatment duration is not reduced but still requires 105 
daily intake of high allergen doses for three years, leading to considerable treatment costs.12 106 
Therefore, treatment compliance with SLIT is low and only 15% of the patients finish the the 107 
full course of treatment.23  108 
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We therefore propose epicutaneous allergen-specific immunotherapy (EPIT) as a novel 109 
needle-free and potentially self-administrable treatment route for SIT using topical 110 
application of an allergen-extract under a patch. Good accessibility, important immune-111 
surveillance function24 with high density of antigen-presenting Langerhans cells in the 112 
epidermis,25 make this outermost layer of the skin a very attractive target organ for 113 
administration of SIT. Also, the lack of vascularisation of the epidermis25 minimizes the risk 114 
for inadvertent intravascular allergen injection and therefore systemic allergic side effects. 115 
First evidence for the effectiveness of EPIT was provided in the 1950s by French 116 
allergologists, who successfully treated their patients by application of allergen drops on 117 
scarified skin.26-27 Our group has recently revisited this approach and confirmed its 118 
effectiveness in a double blind placebo controlled pilot trial.28 We replaced ‘scarification’ by 119 
a more gentle method to remove the stratum corneum, i.e. by adhesive tape-stripping. 120 
Physical removal of at least part of the stratum corneum is important not only to enhance 121 
antigen penetration 29 but also to activate keratinocytes to produce pro-inflammatory 122 
cytokines.25 The present study aimed to define the optimal dose and safety of EPIT for grass 123 
pollen allergy in a larger patient population.   124 
 125 
 126 
 127 
128 
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METHODS 129 
 130 
Trial population 131 
A total number of 157 subjects were screened and 132 patients aged between 18 and 65 years 132 
with a history of grass-pollen allergic rhinoconjunctivitis and positive reactions to grass-133 
pollen extract in the skin prick test (SPT) and conjunctival provocation test (CPT) signed 134 
informed consent. Exclusion criteria were eczematous skin lesions on the upper arms; 135 
perennial allergic rhinitis; infectious rhinitis within the last two weeks, surgical intervention 136 
within the last 30 days; pregnancy or nursing; hypertension; history of HIV/AIDS; 137 
mastocytosis; malignancy; active infectious disease; significant cardiovascular, pulmonary, 138 
renal, hepatic, hematologic, autoimmune, neurological or psychiatric disease; moderate to 139 
severe asthma; intake of antihistamines with long half-live within the last 2 weeks or 140 
corticosteroids within the last 5 days; intake of contraindicated medication for specific 141 
immunotherapy such as β-blockers or angiotensin-converting enzyme/antgiotensin II receptor 142 
antagonists, tricyclic antidepressants; and participation in another clinical trial within the last 143 
60 day. The study was reviewed and approved by the local ethics committee and notified by 144 
Swissmedic, the regulatory agency. ClinicalTrials.gov no. NCT00719511 145 
 146 
Clinical trial design and study procedure 147 
This single center phase I/II randomized, placebo-controlled, double-blind study was 148 
designed to test the efficacious dose range, tolerability and safety as well as the sustained 149 
treatment effect of EPIT. On the basis of a random-number table, 132 grass-pollen allergic 150 
patients were allocated to the placebo group (n=33), the low-dose grass-extract treatment 151 
group (10HEP, n=33), the medium-dose grass-extract treatment group (50HEP, n=33) or the 152 
high-dose grass-extract treatment group (100HEP, n=33).   153 
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The study was performed between February 2008 and November 2009 at the University 154 
Hospital of Zurich. The trial design is outlined in Table I. At the screening visit, patients 155 
having signed informed consent received a brief physical examination. Skin prick test (SPT) 156 
and conjunctival provocation test (CPT) were performed to confirm grass-pollen allergy and 157 
to determine the baseline values. At least four weeks before the start of the 2008 pollen 158 
season patients received the first patch. Prior to patch administration, the application site on 159 
the upper arm or shoulder was tape-stripped 6 times with a scotch tape (3M Company, St 160 
Paul, Minnesota, USA). Following such skin preparation, the allergen containing patch was 161 
applied and patients were observed in the trial facility for 30 minutes. All patients were 162 
handed an emergency-set containing corticosteroids (Prednisone [Streuli, Uznach, 163 
Switzerland]) and antihistamines (Semprex, [GlaxoSmithKline, Brentford, United 164 
Kingdom]). After 8 hours, the patch was removed by the patient. To assess local reactions, all 165 
patients were contacted by phone 48 hours after application of the first patch. With the start 166 
of the pollen season, the following patches were administered in weekly intervals (allowed 167 
range was 5 days to 2 weeks) until treatment completion after application of the 6th patch. 168 
Each patch was administered at a different location on the upper extremity. If a local reaction 169 
occurred, patients were asked to take a photograph and to contact the study site. During the 170 
entire pollen season severity of hay fever symptoms was recorded weekly on a visual 171 
analogue scale and use of rescue medication was assessed daily. This study was conducted in 172 
accordance with the International Conference on Harmonisation guidelines on Good Clinical 173 
Practice and the Declaration of Helsinki. 174 
 175 
Test drug, dosing and patch system 176 
Grass allergen extract derived from pollen of Holcus lanatus, Dactylis glomerata, Lolium 177 
perenne, Phleum pratense, Poa pratensis and Festuca elatior dissolved in a glycerinated 178 
solution (MG51 Mezcal 6 Graminees, Inmunotek, Madrid, Spain) was used as the test drug. 179 
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Patches with different biological activity (10HEP = 1 x prick test concentration, 76 µg/ml; 180 
50HEP = 1 x atopy patch test concentration, 378 µg/ml; 100HEP = 2 x atopy patch test 181 
concentration, 757 µg/ml) were produced by the Cantonal Pharmacy, Canton of Zurich 182 
(Zurich, Switzerland) through integration of the allergenic grass-extract into a patch system 183 
provided by Medanz Medical GmbH (Starnberg, Germany). The patch was 95 mm x 95 mm 184 
in size containing a centred 50 mm x 30 mm sized fibrous web with the adsorbed allergen 185 
extract.  186 
 187 
Efficacy measurements 188 
The main objective of this study was to evaluate the optimal treatment dose as well as 189 
treatment efficacy of EPIT after a one-year treatment period consisting of the application of 6 190 
patches. The primary endpoint was the determination of general improvement / deterioration 191 
of hay fever symptoms after the treatment season 2008 and the treatment-free follow-up year 192 
2009 when compared to previous years. Secondary outcome measures were average visual 193 
analogue scale (VAS) symptom scores obtained as weekly records during the pollen season, 194 
use of rescue medication and changes in CPT and SPT as well as safety measures. 195 
 196 
Patient-reported treatment outcome: improvement / deterioration of hay fever 197 
symptoms on VAS 198 
At visit 7 and visit 9 patients were asked to rate the general improvement / deterioration of 199 
hay fever symptoms on a 200 mm VAS ranging from -100 (worst conceivable symptom 200 
deterioration) over 0 (unchanged symptoms) to +100 (best conceivable symptom 201 
improvement, total symptom relief). 202 
 203 
Symptom and medication diary  204 
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During the pollen seasons 2008 and 2009 patients were asked to record the severity of nasal 205 
itching, sneezing, nasal obstruction, rhinorrhea, itchy eyes, lacrimation, itchy ears, itchy 206 
palate and lung symptoms on a 100 mm VAS ranging from 0 (no symptoms) to 100 (most 207 
severe symptoms) on a weekly basis. To assess the average weekly symptom scores, the sum 208 
of all symptoms (except lung symptoms) was calculated and divided by the total number of 209 
symptoms. Concomitantly, the daily use of provided rescue medication was assessed. 210 
Antihistamines up to 1 tablet daily (Aerius, 5mg, [Essex, Luzern, Switzerland]), 211 
antihistamine eye drops up to 1 drop per eye twice a day (Opatanol, 1mg/ml, [Alcon, 212 
Hünenberg, Switzerland]), nasal corticosteroids up to 2 puffs per nostril twice a day 213 
(Nasonex, 50µg/dose [Essex]) and inhalative corticosteroids up to 2 puffs twice daily 214 
([Symbicort, 200µg AstraZeneca, Zug, Switzerland]). Start and end of the grass pollen 215 
season (28 April – 29 July 2008 and 4 May – 5 July 2009, 9 weeks each) was determined 216 
according to the seasonal development of the pollen load as measured by the Swiss national 217 
weather service (MeteoSwiss).  218 
 219 
Conjunctival provocation test  220 
CPT was performed at baseline as well as at visit 7 and 9. Before testing, the patients were 221 
adapted to room temperature for at least 10 minutes. Unspecific hyperresponsiveness was 222 
excluded by administration of 50 µl of the diluent. Subsequently 50 µl of increasing 223 
allergenic activity of grass-pollen extract (MG 51 6 Graminees, Inmunothek, Spain, Madrid) 224 
was administered into the lower conjunctival sac every 10 minutes, while alternating between 225 
the two eyes. Challenge was stopped when a positive reaction defined as a total symptom 226 
score ≥3 was recorded. Conjunctival redness, tearing, itching, burning and swelling of the 227 
eyelids were assessed and graded each after the protocol of Abelson30 (absent = 0, slight = 1, 228 
definite = 2, severe = 3). At screening, patients were challenged with 5, 50, 500, 5000 229 
biological units (BU). At the post treatment visits, 12500 and 25000 BU were included as 230 
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additional challenge doses, if the lower doses (5 BU – 5000 BU) did not induce a positive 231 
reaction.  232 
 233 
Skin prick test  234 
SPT was performed at baseline as well as at visit 7 and visit 9. Subjects were skin-pricked 235 
with different concentrations of grass-pollen extract 0.05HEP, 0.5HEP, 5HEP, 50HEP 236 
(MG51 Mezcal 6 Graminees, Inmunotek, Madrid, Spain) on the volar forearm. At the 237 
screening visit, polysensitization was tested by performing SPT for mugwort, hazel, birch, 238 
alder, ash, cat hair, dog hair, dermatophagoides pteronyssinus, and dermatogphagoides 239 
farinae (Stallergènes, Antony, France). Histamine hydrochloride and normal saline 240 
(Stallergènes, Antony, France) were used as positive and negative control, respectively. The 241 
SPT results were assessed according to the guidelines of the American Academy of Allergy, 242 
Asthma and Immunology, considering an erythema of 3-5 mm and a wheal of 2-3 mm as a 243 
positive reaction31. To grade the reaction, the classification system of Ring32 was adopted.  244 
 245 
Safety assessment  246 
Adverse events and serious adverse events were defined according to the International 247 
Conference of Harmonization of Good Clinical Practice guidelines. Systemic side effects 248 
related to EPIT were graded according to the guideline of the WAO33. Grade 1: Symptoms of 249 
1 organ system (cutaneous, upper respiratory tract, conjunctival, other), grade 2: Symptoms 250 
of more than 1 organ system present or lower respiratory tract (< 40 PEF or FEV1 drop), 251 
gastrointestinal; Grade 3: lower respiratory tract (40% PEF or FEV1 drop), upper respiratory 252 
(laryngeal, tongue edema); Grade 4: respiratory or cardiovascular failure. 253 
 254 
Statistical analysis 255 
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The sample size calculation was performed assuming a mean self-reported improvement of 256 
29% (SD = 27%) of the placebo group and a mean self-reported improvement of 52% (SD = 257 
27%) in at least one treatment arm. Thus, to yield a statistically significant result with a 258 
power of 82% (2-sided analysis with α = 0.025) and an expected drop out rate of 10%, a 259 
sample size of 33 per arm (total: 132) was calculated.  260 
The scores from the VAS for the improvement / deterioration of hay fever symptoms were 261 
analyzed using Mann-Whitney multiple testing with Hochberg procedure adjustment. For 262 
evaluation of the seasonal VAS symptom scores, the area under the curve (AUC), assessed 263 
out of the average weekly VAS scores, was calculated for each patient. Simultaneous upper 264 
one-sided 97.5% confidence limits for the ratios to placebo were calculated to identify the 265 
minimum effective dose to achieve a 30% improvement (ratio 0.7) of the average VAS 266 
symptom score compared to placebo. For clinically beneficial values, the upper one-sided 267 
limits should thus be smaller than 1. Daily medication use was compared between the groups 268 
using the Kruskal Wallis test. Equal distribution of local side effects at the patch application 269 
site with increasing patch number was tested by chi-sqare test. All subjects with at least one 270 
application of the patch were evaluated for efficacy in an intention-to-treat analysis. 271 
Similarly, all subjects receiving at least one patch were included in the safety analysis.  272 
273 
Senti                                                                                                                                          13 
RESULTS 274 
 275 
Patient characteristics 276 
An overview over the participant flow during study progress is provided in Figure 1. From 277 
February to March 2008 a total of 132 grass-pollen allergic patients signed informed consent 278 
and were enrolled in the study. A total of 33 patients were randomly allocated to each of the 279 
four treatment arms. Mean treatment duration lasted 83 ± 3 days. In the placebo group, 30 280 
patients received at least one patch during the pollen season 2008 and were therefore 281 
included in the intention-to-treat analysis. Similarly, 31 patients each of the 10HEP and 282 
100HEP and 32 patients of the 50HEP group received treatment during 2008 and were 283 
analyzed for treatment efficacy (2008, n = 110 in total). For the follow-up, several patients 284 
were either unable to come to the follow-up visits in 2009 or they needed to be excluded 285 
from the study due to intake of not permitted medication. Thus, a total of 22 patients of each 286 
the placebo and the 10HEP treatment group as well as a total of 25 and 24 patients of the 287 
50HEP and 100HEP group, respectively, were included in the efficacy analysis for evaluation 288 
of sustained treatment effect (2009, n = 93 in total). At baseline, the demographic- as well as 289 
the disease-specific characteristics were similar between the four treatment groups with 290 
regards to disease duration, allergic asthma and co-sensitization to other allergens. Disease 291 
severity, as well, revealed to be comparable at baseline between the groups, presenting all 292 
with a history of moderate to severe rhinitis according to the ARIA guidelines as assessed by 293 
VAS34 (Table II).  294 
 295 
Efficacy 296 
Patient reported treatment outcome  297 
As primary endpoint we assessed the general impact of EPIT on grass-pollen allergy by 298 
determination of the subjectively experienced improvement or deterioration of hay-fever 299 
Senti                                                                                                                                          14 
symptom severity as assessed by VAS. After the first year we observed a general 300 
improvement of hay fever symptoms in all the treatment groups, including the placebo group 301 
(Fig. 2). Yet, after the ‘treatment-free’ follow-up year, the marked placebo effect observed in 302 
2008 vanished, revealing a clear dose-response relationship 2009 (median improvement 303 
placebo 30.73, 10HEP group 30.73, 50HEP group 53.13, 100HEP group 69.79) Symptom 304 
alleviation for the high-dose treatment group was statistically significant when compared to 305 
placebo treated group (placebo-10HEP: p=0.532; placebo-50HEP: p=0.141, placebo-100-306 
HEP: p=0.017) (Fig. 2).  307 
 308 
Weekly seasonal symptom and medication score 309 
During the treatment season 2008 the average weekly rhinoconjunctivitis symptom score was 310 
reduced by 32% (estimate 0.68, upper 97.5% CI = 1.09) in the 100HEP treatment group 311 
compared to the placebo group (Fig. 3). After the treatment-free follow-up year, the 100HEP 312 
group still experienced a 24% reduction of the average seasonal symptom score (estimate 313 
0.77, upper 97.5% CI = 1.60) as compared to the placebo group. Again, a dose response 314 
relationship was observed for the reduction of seasonal symptom scores in 2009. The use of 315 
rescue medication (Desloratadin [Aerius], Olopatadin [Opatanol], Mometasone furoate 316 
[Nasonex] and Budenoside with Formoterole [Symbicort]) did not significantly differ 317 
between the different treatment groups neither during the pollen season 2008 nor during the 318 
pollen season 2009.  319 
 320 
Conjunctival provocation test and skin prick test 321 
In the CPT, no statistically significant difference in the degree of improvement was observed 322 
between the different treatment groups. Likewise, no significant difference was seen in SPT 323 
reaction thresholds. 324 
  325 
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Safety  326 
During the entire study period a total of 1566 AEs were reported, of which 825 (52.7%) were 327 
graded as likely/definite drug-related. The most frequent likely/definite drug-related AEs 328 
were pruritus (417 events, 26.6% of total AEs), erythma (90 events, 5.7% of total AEs), 329 
wheals (149 events, 9.5% of total AEs) or eczema (138 events, 8.8% of total AEs); all 330 
occurring at the patch application site. Pruritus, erythema, wheals and eczema were observed 331 
with increasing frequency the higher the allergen treatment dose (Fig. 4a). Interestingly 332 
however, the occurrence of such local drug-related AEs significantly decreased with each 333 
patch application in all the treatment groups (P < 0.001)(Fig. 4b). 334 
Eleven patients (8.3%) stopped treatment due to a systemic allergic reaction, which 335 
necessitated patch removal and administration of corticosteroids and antihistamines. Of these 336 
11 patients, 1 had received placebo, whereas 10 had been treated with allergen extract (Tab. 337 
IV). All reactions were rated as grade 1 or grade 2. All presented with cutaneous reactions 338 
such as sustained pruritus distant from the patch application site and sensation of heat, 339 
whereas four patients additionally suffered from rhinitis and cough originating in the upper 340 
airways, or vertigo. All these systemic reactions responded to treatment with corticosteroids 341 
and antihistamines. None of these reactions required administration of adrenaline and none of 342 
these reactions were life-threatening or needed hospitalisation at any time.  343 
 344 
 345 
346 
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DISCUSSION 347 
 348 
The fact that allergic diseases constitute a global health problem with considerable impact on 349 
socioeconomic life4, 7 underlines the need to develop a novel and convenient route for SIT 350 
with high efficacy and broad acceptance. Since the burden of allergic diseases goes beyond 351 
symptom scores and medication use but also affects quality of life, we chose the Patient-352 
Reported Outcome (PRO) measure: ‘improvement / deterioration of hay fever symptoms by 353 
VAS’ as primary endpoint. Masked by a high placebo effect during the treatment year, the 354 
dose-dependent increase of self-reported overall treatment success became obvious only after 355 
a treatment-free follow-up year. With a median improvement of 70%, statistical and clinical 356 
significance was reached for the highest treatment dose group (100HEP) in comparison to the 357 
placebo group. Interestingly, the assessment of the seasonal rhinoconjunctivitis symptom 358 
scores was less subjected to the placebo effect, as average symptom scores were reduced in 359 
the 100HEP by more than 30% (as compared to the placebo group), already during the 360 
treatment year and by 24% after the follow-up year.  361 
Although statistical significance for self-reported symptom improvement was only reached 362 
for the high dose treatment group, it is important to consider that statistical significance does 363 
not parallel clinical treatment benefit under real-life conditions. Therefore, it has been 364 
proposed that every improvement of > 30% is clinically relevant. Correspondingly, an 365 
improvement between 30 – 45% is judged as ‘little’ treatment effect, whereas an 366 
improvement between 46 – 60% is assessed as ‘moderate’ treatment effect and an 367 
improvement > 60% as ‘strong’ effect.35 According to such rating, treatment effect was 368 
strong in the 100HEP, moderate in the 50HEP group and absent in the 10HEP group. 369 
Strikingly, such clinically relevant effect was achieved through application of merely 6 370 
patches during a single pollen season.  371 
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Overall, EPIT proved to be safe, but not without systemic allergic side effects, which 372 
required treatment and led to study exclusion in 9% of the treated population. Yet, all of these 373 
systemic allergic reactions were mild (grade I to grade II) and occurred within 45 minutes 374 
after patch application. Compared to conventional SCIT, which is associated with a 30% risk 375 
of systemic allergic reactions (graded from mild to life-threatening),36 the safety profile of 376 
EPIT appears better. Local reactions at the patch application site were frequently reported 377 
and mostly presented as pruritus, erythema, wheal and eczema. Although bothersome, the 378 
appearance of an eczematous skin reaction demonstrates the elicitation of an allergen-specific 379 
T cell response.37-38 Such cellular immune-activation and potential immune-deviation is a 380 
crucial mechanism in SIT, which aims at re-directing the allergic T-helper (Th) 2 response 381 
toward a Th1 or T-regulatory (Treg) cell response39-40. Interestingly, over time, we observed 382 
a decrease of such local treatment-associated AEs, which might indicate reduction of 383 
allergen-specific T cell reactivity and development of peripheral T cell tolerance. Since 384 
induction of T cell tolerance has been demonstrated to be a key mechanism of efficacious 385 
SCIT39 and SLIT41-43  it might also play an important role in EPIT. To investigate the 386 
immunological changes associated with EPIT, such as induction of blocking antibodies and 387 
peripheral T reg cells, a subsequent trial has been initiated (NCT00777374). First results are 388 
expected in 2011.  389 
The present trial reproduces the results of our first and smaller clinical trial on EPIT28 with a 390 
larger patient number. As an improvement over our first clinical trial we could reduce the 391 
number of patch applications from 12 to 6, and the duration of each single patch application 392 
from 48 hours to 8 hours. 393 
In summary, our data provide evidence for the dose-dependent efficacy of EPIT as needle-394 
free, rapid and self-administrable treatment option for IgE-mediated allergies. ‘Epicutaneous’ 395 
allergen-specific immunotherapy further extends the steadily growing application field of 396 
needle-free vaccination methods delivering the antigen via the skin. ‘Transcutaneous’ 397 
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vaccination against infectious diseases such as travellers’ diarrhea44 and influenza45 are 398 
examples of this novel and promising vaccination route. Furthermore, ‘percutaneous’ peptide 399 
immunization has been shown to be successful in cancer therapy.46 In line with these, 400 
epicutaneous allergen-specific immunotherapy may considerably contribute to combat one of 401 
the ‘new epidemics of the 21st century’. Its easy and painless administration might promote 402 
the increased prescription of SIT in children, which is an important goal, since SIT has the 403 
potential to stop the ‘atopic march’ and disease progression to asthma.47 EPIT therefore has 404 
the potential to reduce the socio-economic burden of allergies when administered early in the 405 
course of the disease.48  406 
407 
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Table I. Study outline  
 
Visit/time 
 
Intervention/analysis 
February/March 2008 Newspaper advertisement and telephone recruitment 
 
Screening (March-April 2008) Medical history and examination, CPT, SPT, Severity 
assessment of rhinoconjunctivitis with VAS 
 
Visit 1 (March-April 2008) First patch application 
Follow-up call after 48 h for record of local AEs 
 
Visit 2 (April-May 2008) Second patch application, AE records 
 
Visit 3 – 6 (May-July 2008) (Bi-)weekly patch application, AE records 
Weekly VAS symptom diary, Medication diary 
 
Visit 7 (August-September 2008) Medical examination, CPT, SPT, AE records, 
Recording of improvement / deterioration VAS 
Visit 8 (March-May 209) AE records 
 
Pollen season 2009 Weekly VAS symptom diary, Medication diary 
 
Visit 9 (September-November 2009) Medical examination, CPT, SPT, AE records, 
Recording of improvement / deterioration on VAS 
 
VAS = visual analogue scale, CPT = conjunctival provocation test, SPT = skin prick test, AE 
= adverse event 
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Table II. Baseline characteristics     
  
Treatment group 
 
Characteristics 
 
Placebo 
 
10HEP 
 
50HEP 
 
100HEP 
Age (y), mean ± SD 39 ± 10.8 35 ±11.3 36 ± 10.2 36  ± 10.6 
Female, n (%) 9 (27.3) 14 (42.4) 11 (33.3) 15 (45.5) 
Duration of rhinitis (years), mean ± SD 23 ± 11.6 21 ± 11.2 21  ± 10.5 21 ± 10.6 
Severity of rhinoconjunctivitis, 
mean total VAS ± SD 
53 ± 14.9 47 ± 16.7 50 ± 17 51 ± 18.5 
 Severity of nasal symptoms 
mean VAS ± SD 
60 ± 19.8 56 ± 19.5 57 ± 24.0 56 ± 18.9 
 Severity of ocular symptoms 
mean VAS ± SD 
63 ± 20.1 52 ± 25.3 55 ± 19.0 52 ± 26.5 
 Severity oro-pharyngeal 
symptoms mean ± SD 
28 ± 24.0 24 ± 24.2 31 ± 29.8 38 ± 26.7 
Severity of lung symptoms  
mean VAS ± SD 
38  ±33.7 24 ± 31.4 25 ± 28.9 24 ± 31.2 
Seasonal asthma (%) 9 (27.3) 9 (27.3) 12 (36.4) 10 (30.3) 
Monosensitized patients 7 (21.2) 5 (15.2) 11 (33.3) 7 (21.2) 
Polysensitized patients 26 (78.8) 28 (84.8) 22 (66.7) 26 (78.8) 
Baseline CPT threshold, mean ± SD     
 5  BU 2 ± 6.1 1 ± 3.0 1 ± 3.0 1 ± 3.0 
 50 BU 5 ± 15.2 3 ± 9.1 8 ± 24.2 10 ± 30.3 
 500 BU 21 ± 63.6 21 ± 63.6 19 ± 57.6 11 ± 33.3 
 5000 BU 5 ± 15.2 8 ± 24.2 5 ± 15.2 11 ± 33.3 
Baseline SPT, threshold, mean ± SD     
 0.05 HEP 15 (45.5) 11 (33.3) 12 (36.4) 10 (30.3) 
 0.5 HEP 6 (18.2) 11 (33.3) 1133.3) 7 (21.2) 
 5 HEP 11 (33.3) 10 (30.3) 9 (27.3) 8 (24.2) 
 50 HEP 1 (3.0) 1 (3.0) 1 (3.0) 8 (24.2) 
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Table III. Adverse events     
  
Treatment groups 
 
 
Adverse events 
 
Placebo 
(n = 33) 
 
10HEP 
(n = 33) 
 
50HEP 
(n=33) 
 
100HEP 
(n=33) 
Number of patients with AE, n (%) 33 (100) 33 (100) 33 (100) 33 (100) 
Number of AE episodes 279 409 427 451 
Causality assessment     
 No relation, n (%) 14 (5.0) 14 (3.4) 18 (4.2) 11 (2.4) 
 Unlikely/Possible relation, n (%) 182 (65.2) 191 (46.7) 162 (37.9) 148 (32.8) 
 Likely/Definite, n (%) 82 (29.4) 204 (49.9) 247 (57.8) 292 (64.7) 
 Missing, n (%) 1 (0.4) 0 0 0 
Severity assessment of  
Likely/definite drug related AEs 
    
 mild, n (%) 60 (76.9) 135 (66.2) 139 (56.3) 147 (50.3) 
 moderate, n (%) 14 (17.9) 58 (28.4) 82 (33.2) 115 (39.4) 
 severe, n (%) 4 (5.1) 11 (5.4) 26 (10.5) 30 (10.3) 
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Table IV. Systemic allergic reactions necessitating intervention* 
 
  
Treatment groups 
  
Placebo 
(n=33) 
 
10HEP 
(n=33) 
 
50HEP 
(n=33) 
 
100HEP 
(n=33) 
Systemic allergic reaction     
 grade 1, n  1 1 3 2  
 grade 2, n  0 2  2 
 grade 3, n  0 0 0 0 
 grade 4, n  0 0 0 0 
* treated with corticosteroids and antihistamines 
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Figure legends 
 
Figure 1. Participant flow. 
Flow diagram characterizing the study progress and participant flow through the different trial 
phases. 
 
Figure 2. Patient reported treatment outcome. 
Patients rated the general improvement / deterioration of hay fever symptoms on a scale from 
-100 (worst possible deterioration) to +100 (best possible improvement) during the seasons 
2008 (treatment) and 2009 (follow-up). Box plots show the median, the 10th, 25th, 75th, 90th 
percentiles and outliers. Intergroup comparison by Mann-Whitney multiple testing with 
Hochberg procedure adjustment.*, P < 0.05 
 
Figure 3. Mean VAS symptom score for pollen season 2008 and 2009 
Mean weekly VAS symptom scores (except lung symptoms) of the 100HEP group compared 
to placebo (left axis). For each patient, the sum of all symptom scores was calculated and 
divided by the number of symptoms. The continuous line shows the weekly pollen counts in 
Zurich (right axis).  
 
Figure 4. Local drug related adverse events 
(A) Number of the most frequent local drug-related adverse events as reported in the different 
treatment groups. (B) Frequency of local side effects per patch sequence. Distribution of the 
frequency of local AEs was tested by chi-square test.  
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